Progyny, Inc. (NASDAQ:PGNY) Receives Average Recommendation of “Moderate Buy” from Analysts

Progyny, Inc. (NASDAQ:PGNY) has been given an average rating of “Moderate Buy” by the ten research firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $25.4444.

Several analysts have issued reports on the stock. Truist Financial increased their target price on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. Wall Street Zen raised Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 target price (up from $26.00) on shares of Progyny in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Progyny in a report on Wednesday, October 8th. Finally, Raymond James Financial set a $28.00 price objective on Progyny in a report on Friday, August 8th.

Progyny Stock Down 4.6%

Shares of NASDAQ PGNY opened at $18.01 on Friday. The company has a market cap of $1.55 billion, a P/E ratio of 30.53, a P/E/G ratio of 1.61 and a beta of 1.29. Progyny has a 52 week low of $13.39 and a 52 week high of $26.76. The business has a 50-day simple moving average of $20.94 and a two-hundred day simple moving average of $21.84.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.24). Progyny had a return on equity of 10.69% and a net margin of 4.28%.The firm had revenue of $313.35 million during the quarter, compared to analysts’ expectations of $299.23 million. During the same period in the previous year, the company posted $0.11 earnings per share. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. Equities research analysts anticipate that Progyny will post 0.6 EPS for the current year.

Insider Activity at Progyny

In other news, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the sale, the director directly owned 12,501 shares of the company’s stock, valued at approximately $275,522.04. The trade was a 16.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Allison Swartz sold 2,398 shares of the stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the completion of the transaction, the executive vice president directly owned 79,697 shares in the company, valued at approximately $1,829,843.12. This represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 7,895 shares of company stock valued at $179,311. 9.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Progyny

Several institutional investors have recently modified their holdings of the company. Cetera Trust Company N.A lifted its position in Progyny by 303.1% in the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock worth $29,000 after buying an additional 985 shares during the last quarter. Federated Hermes Inc. lifted its holdings in shares of Progyny by 147.3% in the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after acquiring an additional 819 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Progyny in the 1st quarter worth approximately $44,000. Militia Capital Partners LP grew its holdings in shares of Progyny by 100.0% during the 1st quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock valued at $45,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Versant Capital Management Inc raised its position in Progyny by 61.8% in the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after purchasing an additional 894 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.